Receptor News and Research

RSS

COPD phase III study by Almirall and Forest Laboratories announces positive results

Almirall, S.A. (ALM:MC) and Forest Laboratories, Inc. (NYSE:FRX) today announced positive topline results from a six month pivotal phase III clinical trial evaluating the efficacy and safety of fixed dose combinations of aclidinium bromide (LAMA) and formoterol fumarate (LABA) delivered by Almirall’s inhaler Genuair® (Pressair™ in the USA).

16 Apr 2013

Montreal scientists identify potential target to reduce progression of metastases in breast cancer patients

A team of researchers at the IRCM, led by Dr. Jean Franois Ct, made an important discovery in breast cancer, which will published online this week by the scientific journal Proceedings of the National Academy of Sciences (PNAS).

16 Apr 2013

Monell Center molecular neurobiologist to receive Ajinomoto Award for Young Investigators in Gustation

Monell Center molecular neurobiologist Peihua Jiang, PhD, is the 2013 recipient of the Ajinomoto Award for Young Investigators in Gustation, an annual award presented by the Association for Chemoreception Sciences (AChemS) to an exceptional junior scientist who is a rising leader in the field of gustation.

16 Apr 2013

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Recently, doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment.

16 Apr 2013

MD Anderson researcher awarded 2013 Fight Colorectal Cancer-AACR Fellowship

For her research focusing on the refinement of predictive biomarkers and improving outcomes in the field of metastatic colorectal cancer, Maria Pia Morelli, M.D., Ph.D., has been awarded the 2013 Fight Colorectal Cancer-AACR Fellowship, in memory of Lisa Dubow.

16 Apr 2013

Death of heart tissue could be prevented with new medicines, say TUSM scientists

A major factor in the advance of heart disease is the death of heart tissue, a process that a team of scientists at Temple University School of Medicine's Center for Translational Medicine think could be prevented with new medicines.

15 Apr 2013

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease.

15 Apr 2013

Study shows more women develop chronic low back pain, sciatica than men

More women than men develop chronic low back pain and sciatica. The explanation may lie with a gene variant that plays into the body's pain regulation.

12 Apr 2013

Nalmefene can provide important clinical benefit for alcohol-dependent patients

A potential new treatment for alcoholism called nalmefene is effective and safe for reducing alcohol consumption in alcohol dependent individuals, says a new study published this week in Biological Psychiatry.

12 Apr 2013

Discovery suggests new therapeutic target for treating dysfunctional beta cells, type 2 diabetes

Researchers at the University of California, San Diego School of Medicine have identified a previously unknown biological mechanism involved in the regulation of pancreatic islet beta cells, whose role is to produce and release insulin.

12 Apr 2013

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

The scientist whose discoveries led to the first drug approved for metastatic melanoma by "treating the immune system, not the cancer," also is the first to receive the AACR-CRI Lloyd J. Old Award in Cancer Immunology.

12 Apr 2013

Androgen receptors found to be a potential target in breast cancer

Estrogen and progesterone receptors, and the gene HER2 - these are the big three markers and/or targets in breast cancer. Evidence presented at the AACR Annual Meeting 2013 adds a fourth: androgen receptors.

11 Apr 2013

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Omeros Corporation today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds for the treatment of MS. Compounds previously discovered by Omeros that inhibit GPR17, an orphan G protein-coupled receptor (GPCR) unlocked by Omeros, significantly improved function from experimental autoimmune encephalomyelitis (EAE) in mice.

11 Apr 2013

Study shows genetic variant reduces pain severity associated with sexual assault

One in five U.S. women are sexually assaulted in their lifetimes and more than half experience severe pain during the week following an attack.

11 Apr 2013

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.

10 Apr 2013

Scientists show link between modifiable factors and breast cancer risk among African-Americas

Evidence has shown for decades that African-American women with breast cancer have poorer outcomes than women of European descent, but even robust genomic studies have not identified clear links that might explain these trends.

10 Apr 2013

Research shows UNC1062 blocks Mer survival signaling in melanoma cells

Collaborative research presented by the University of Colorado Cancer Center, the University of North Carolina at Chapel Hill, Harvard Medical School and the University of Pittsburgh, at the American Association for Cancer Research Annual Conference, shows that the protein receptor Mer is overexpressed in melanoma and that the investigational drug UNC1062 blocks Mer survival signaling in these cells, killing them.

10 Apr 2013

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

The Jeffrey Epstein VI Foundation, a science foundation based in New York City, has helped finance the first mathematical model of how human cancer cells evolve, and more specifically, how they evolve to become immune to inhibitor drug therapy, a popular alternative to chemotherapy.

10 Apr 2013

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor, fuels a wide variety of cancers-including a highly malignant brain cancer known as glioblastoma.

9 Apr 2013

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

The mammalian target of rapamycin, mTOR is a central integrator of the cell that coordinates growth factor receptor signaling with energy and nutrient status to control a wide array of activities, including the regulation of cellular proliferation and survival.

9 Apr 2013

Receptor News and Research

COPD phase III study by Almirall and Forest Laboratories announces positive results

Montreal scientists identify potential target to reduce progression of metastases in breast cancer patients

Monell Center molecular neurobiologist to receive Ajinomoto Award for Young Investigators in Gustation

Researchers develop nanodiamond delivery system for triple-negative breast cancer

MD Anderson researcher awarded 2013 Fight Colorectal Cancer-AACR Fellowship

Death of heart tissue could be prevented with new medicines, say TUSM scientists

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Study shows more women develop chronic low back pain, sciatica than men

Nalmefene can provide important clinical benefit for alcohol-dependent patients

Discovery suggests new therapeutic target for treating dysfunctional beta cells, type 2 diabetes

UT MD Anderson scientist receives AACR-CRI Lloyd J. Old Award in Cancer Immunology

Androgen receptors found to be a potential target in breast cancer

Omeros' GPCR platform unlocks new drug targets against multiple sclerosis

Study shows genetic variant reduces pain severity associated with sexual assault

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Scientists show link between modifiable factors and breast cancer risk among African-Americas

Research shows UNC1062 blocks Mer survival signaling in melanoma cells

Jeffrey Epstein VI Foundation helps develop mathematical model to study evolution of cancer

Researchers explore how blocking EGFR changes signaling in glioblastoma cells

Mammalian target of rapamycin (mTOR) pathway: an interview with Dr. Paul Mischel, Ludwig Institute for Cancer Research

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News